David Nierengarten
Stock Analyst at Wedbush
(4.38)
# 327
Out of 5,154 analysts
216
Total ratings
53.67%
Success rate
16.99%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Maintains: Outperform | $4 → $8 | $5.99 | +33.56% | 2 | Mar 6, 2026 | |
| TCRX TScan Therapeutics | Maintains: Outperform | $4 → $5 | $1.12 | +346.43% | 5 | Mar 5, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $90 → $95 | $73.05 | +30.05% | 4 | Mar 3, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 → $65 | $26.54 | +144.91% | 4 | Feb 25, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $50 → $53 | $46.16 | +14.82% | 6 | Feb 25, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $13.71 | +45.88% | 10 | Feb 24, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Underperform | $110 | $109.33 | +0.61% | 1 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Outperform | $110 → $88 | $61.18 | +43.84% | 5 | Feb 17, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.59 | +139.65% | 12 | Feb 10, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.97 | +121.33% | 5 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $37.08 | +48.33% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $21.04 | +47.34% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $18 | $13.04 | +38.04% | 9 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $717.79 | +39.32% | 24 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $18.47 | +62.43% | 3 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $10.42 | +139.92% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $13.44 | -47.92% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.33 | +426.32% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $99.41 | +15.68% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.32 | +129.68% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.52 | +192.55% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $15.12 | -47.09% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $25.29 | -20.92% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $55.41 | -27.81% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $45.29 | +3.78% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $32.97 | +21.32% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $40.15 | +12.08% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.74 | +213.59% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.01 | +199.25% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.27 | +21,926.43% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $8.77 | +584.15% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.70 | +146.75% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $21.25 | +252.94% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.13 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.90 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.59 | - | 3 | Nov 20, 2017 |
Shattuck Labs
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $5.99
Upside: +33.56%
TScan Therapeutics
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.12
Upside: +346.43%
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $73.05
Upside: +30.05%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $26.54
Upside: +144.91%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Outperform
Price Target: $50 → $53
Current: $46.16
Upside: +14.82%
ORIC Pharmaceuticals
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $13.71
Upside: +45.88%
ABIVAX Société Anonyme
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $109.33
Upside: +0.61%
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $61.18
Upside: +43.84%
Nuvation Bio
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.59
Upside: +139.65%
Perspective Therapeutics
Jan 30, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.97
Upside: +121.33%
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $37.08
Upside: +48.33%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $21.04
Upside: +47.34%
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $13.04
Upside: +38.04%
Jan 14, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $717.79
Upside: +39.32%
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $18.47
Upside: +62.43%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $10.42
Upside: +139.92%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $13.44
Upside: -47.92%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.33
Upside: +426.32%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $99.41
Upside: +15.68%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $11.32
Upside: +129.68%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $7.52
Upside: +192.55%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $15.12
Upside: -47.09%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $25.29
Upside: -20.92%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $55.41
Upside: -27.81%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $45.29
Upside: +3.78%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $32.97
Upside: +21.32%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $40.15
Upside: +12.08%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $5.74
Upside: +213.59%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.01
Upside: +199.25%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.27
Upside: +21,926.43%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $8.77
Upside: +584.15%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.70
Upside: +146.75%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $21.25
Upside: +252.94%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.90
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.59
Upside: -